{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Illumina, Inc.
Illumina, Inc. Hits New 52-Week High at USD 165.37
Illumina, Inc. has achieved a new 52-week high, reflecting strong performance with a one-year gain significantly exceeding the S&P 500. The company, with a market cap of USD 22,890 million, showcases solid financial health, evidenced by a low debt-to-equity ratio and a high return on equity.
Illumina, Inc. Hits Day High with Strong 5.68% Intraday Surge
Illumina, Inc. has experienced notable stock performance, significantly outperforming the S&P 500 over various time frames. The company boasts a strong financial position, highlighted by its net-debt-free status and impressive operating cash flow. High institutional ownership further enhances its market standing within the Pharmaceuticals & Biotechnology sector.
Illumina, Inc. Hits New 52-Week High of $158.78, Up 48.7%
Illumina, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year, outpacing broader market growth. With a market capitalization of USD 22,890 million, the company showcases strong financial metrics, including a low debt-to-equity ratio and impressive return on equity, despite not offering dividends.
Illumina, Inc. Hits Day High with 7.13% Surge in Stock Price
Illumina, Inc. has seen a notable increase in its stock performance, reaching an intraday high and outperforming the S&P 500 over the past year. The company maintains a low debt-to-equity ratio and has reported strong operating cash flow, indicating solid financial health despite some long-term growth concerns.
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics
Illumina, Inc. has recently adjusted its valuation, with a P/E ratio of 36 and a price-to-book value of 8.41. Despite a strong one-year return of 63.32%, the company has struggled over three and five years. Its valuation metrics indicate a competitive landscape within the Pharmaceuticals & Biotechnology sector.
Illumina Stock Hits Day Low of $119.16 Amid Price Pressure
Illumina, Inc. saw a significant stock price decline on April 29, 2026, amid a challenging trading session. Despite recent fluctuations, the company maintains a low debt-to-equity ratio and strong financial health, with 100% institutional holdings indicating investor confidence in its fundamentals.
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Illumina, Inc. has recently adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 36 and a PEG ratio of 0.64, indicating favorable growth prospects. The company demonstrates robust profitability with a ROCE of 28.32% and a one-year return of 64.77%, outperforming the S&P 500.
Illumina Stock Hits Day Low of $116.75 Amid Price Pressure
Illumina, Inc. faced a significant stock price decline today, reaching an intraday low. Despite recent short-term challenges, the company has shown strong annual performance and solid financial health, characterized by a low debt-to-equity ratio and positive operating cash flow over the last three quarters.
Illumina Stock Hits Day High with Strong 5.54% Intraday Surge
Illumina, Inc. has experienced notable market activity, achieving a significant intraday high and a robust weekly increase. Over the past year, the company has outperformed the S&P 500, with impressive profit growth and strong financial metrics, including a low debt-to-equity ratio and consistent positive quarterly results.
Is Illumina, Inc. technically bullish or bearish?
As of October 31, 2025, Illumina, Inc. shows a mildly bullish technical trend despite underperforming the S&P 500, with mixed signals from indicators like the MACD and KST suggesting caution.
Is Illumina, Inc. overvalued or undervalued?
As of October 31, 2025, Illumina, Inc. is considered overvalued with a valuation grade of expensive, highlighted by a P/E ratio of 26 and underperformance against the S&P 500, despite a low PEG ratio of 0.07.
Is Illumina, Inc. technically bullish or bearish?
As of October 31, 2025, Illumina, Inc. shows a mildly bullish technical trend supported by positive MACD and Bollinger Bands, despite mixed signals from the KST and concerning long-term performance, with a year-to-date return of -10.21%.
Is Illumina, Inc. overvalued or undervalued?
As of October 31, 2025, Illumina, Inc. is considered overvalued with a P/E ratio of 26, significantly higher than its peers, and has underperformed the S&P 500 with a year-to-date return of -10.21% and a 5-year return of -58.38%.
Illumina Stock Soars 24.78%, Hits Intraday High of $123.91
Illumina, Inc. has seen notable stock activity, with a significant intraday high and a strong weekly performance. Despite recent challenges reflected in longer-term returns, the company reported impressive net profit growth and maintains a low debt-to-equity ratio, indicating a solid financial position amidst market fluctuations.
Illumina, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape
Illumina, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 26 and a Price to Book Value of 6.89. The company demonstrates strong operational efficiency with an EV to EBIT of 12.09 and a ROCE of 44.33%, reflecting its competitive position in the Pharmaceuticals & Biotechnology sector.
Is Illumina, Inc. technically bullish or bearish?
As of October 31, 2025, Illumina, Inc. shows a mildly bullish technical trend supported by bullish MACD and Bollinger Bands, despite some bearish indicators, while outperforming the S&P 500 in the short term but underperforming year-to-date.
Is Illumina, Inc. overvalued or undervalued?
As of October 31, 2025, Illumina, Inc. is considered overvalued with a P/E ratio of 26 compared to the industry average of 19.09, a high EV to EBITDA ratio of 9.89, and a low PEG ratio of 0.07, while its stock has underperformed with a -14.29% return over the past year.
Is Illumina, Inc. technically bullish or bearish?
As of October 31, 2025, Illumina, Inc. shows a mildly bullish technical trend, supported by positive MACD and Bollinger Bands, but mixed signals from KST and OBV suggest caution despite recent outperformance against the S&P 500.
Is Illumina, Inc. overvalued or undervalued?
As of October 31, 2025, Illumina, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 26 and underperformance against the S&P 500, showing a year-to-date return of -7.55% compared to the index's 16.30%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
